# Bioavailability Study of Fexofenadine HCl New Formulation Tablet

> **NCT06284902** · PHASE1 · COMPLETED · sponsor: **Opella Healthcare Group SAS, a Sanofi Company** · enrollment: 25 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Fexofenadine HCl Coated tablet
- **DRUG:** Fexofenadine HCl New Formulation Tablet

## Key facts

- **NCT ID:** NCT06284902
- **Lead sponsor:** Opella Healthcare Group SAS, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-23
- **Primary completion:** 2024-05-08
- **Final completion:** 2024-05-23
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06284902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06284902, "Bioavailability Study of Fexofenadine HCl New Formulation Tablet". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06284902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*